296 related articles for article (PubMed ID: 38393661)
1. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
Veiga RN; de Azevedo ALK; de Oliveira JC; Gradia DF
J Mol Med (Berl); 2024 Apr; 102(4):479-493. PubMed ID: 38393661
[TBL] [Abstract][Full Text] [Related]
2. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
Zhou Y; Sakurai H
Biol Pharm Bull; 2017; 40(10):1616-1624. PubMed ID: 28966234
[TBL] [Abstract][Full Text] [Related]
3. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.
Ruan H; Li S; Bao L; Zhang X
Oncogene; 2020 Sep; 39(38):6113-6128. PubMed ID: 32814829
[TBL] [Abstract][Full Text] [Related]
4. EphA2 as a phase separation protein associated with ferroptosis and immune cell infiltration in colorectal cancer.
Li Y; Peng Q; Wang L
Aging (Albany NY); 2023 Nov; 15(22):12952-12965. PubMed ID: 37980165
[TBL] [Abstract][Full Text] [Related]
5. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.
Zhuang G; Brantley-Sieders DM; Vaught D; Yu J; Xie L; Wells S; Jackson D; Muraoka-Cook R; Arteaga C; Chen J
Cancer Res; 2010 Jan; 70(1):299-308. PubMed ID: 20028874
[TBL] [Abstract][Full Text] [Related]
6. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
7. EphA2-dependent molecular targeting therapy for malignant tumors.
Biao-xue R; Xi-guang C; Shuan-ying Y; Wei L; Zong-juan M
Curr Cancer Drug Targets; 2011 Nov; 11(9):1082-97. PubMed ID: 21933105
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin-Producing Hepatoma Receptor Tyrosine Kinase A2 Modulation Associates with Protective Effect of Prone Position in Ventilator-induced Lung Injury.
Park BH; Shin MH; Douglas IS; Chung KS; Song JH; Kim SY; Kim EY; Jung JY; Kang YA; Chang J; Kim YS; Park MS
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):519-529. PubMed ID: 29216437
[TBL] [Abstract][Full Text] [Related]
9. Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment.
Nehal M; Khatoon J; Akhtar S; Khan MKA
Mol Biol Rep; 2024 Feb; 51(1):337. PubMed ID: 38393520
[TBL] [Abstract][Full Text] [Related]
10. Emerging strategies for EphA2 receptor targeting for cancer therapeutics.
Tandon M; Vemula SV; Mittal SK
Expert Opin Ther Targets; 2011 Jan; 15(1):31-51. PubMed ID: 21142802
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
12. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Amato KR; Wang S; Tan L; Hastings AK; Song W; Lovly CM; Meador CB; Ye F; Lu P; Balko JM; Colvin DC; Cates JM; Pao W; Gray NS; Chen J
Cancer Res; 2016 Jan; 76(2):305-18. PubMed ID: 26744526
[TBL] [Abstract][Full Text] [Related]
13. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
14. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
15. Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation.
Liang S; Wang Q; Wen Y; Wang Y; Li M; Wang Q; Peng J; Guo L
Cancer Sci; 2023 Mar; 114(3):921-936. PubMed ID: 36377249
[TBL] [Abstract][Full Text] [Related]
16. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.
Mao L; Yuan W; Cai K; Lai C; Huang C; Xu Y; Zhong S; Yang C; Wang R; Zeng P; Huang H; Chen Z; Chen Z
Oncogene; 2021 May; 40(20):3610-3623. PubMed ID: 33941853
[TBL] [Abstract][Full Text] [Related]
17. Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.
Moyano-Galceran L; Pietilä EA; Turunen SP; Corvigno S; Hjerpe E; Bulanova D; Joneborg U; Alkasalias T; Miki Y; Yashiro M; Chernenko A; Jukonen J; Singh M; Dahlstrand H; Carlson JW; Lehti K
EMBO Mol Med; 2020 Apr; 12(4):e11177. PubMed ID: 32115889
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.
Annamalai B; Liu X; Gopal U; Isaacs JS
Mol Cancer Res; 2009 Jul; 7(7):1021-32. PubMed ID: 19567782
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
Fan J; Wei Q; Koay EJ; Liu Y; Ning B; Bernard PW; Zhang N; Han H; Katz MH; Zhao Z; Hu Y
Theranostics; 2018; 8(21):5986-5994. PubMed ID: 30613276
[No Abstract] [Full Text] [Related]
20. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
